CRA was retained in an international arbitration between two Japanese affiliates of multinational pharmaceutical companies. The dispute concerned Respondent’s performance under a co-promotion agreement. CRA’s team of life sciences consultants assessed indicators of commercially reasonable efforts using various industry data sources. The CRA team also quantified Claimant’s loss resulting from the alleged inadequate performance under the agreement, and responded to Respondent’s expert regarding damages alleged by Respondent.
CRA recognized in Chambers 2026 for litigation support and crisis & risk management
Charles River Associates has been recognized in the 2026 Chambers Litigation Support and Crisis & Risk Management Guides, including a Band 1 global ranking...

